NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘
Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Gary Phillips, MD, has been appointed as the new chairman of the Company’s supervisory board. Dr. Phillips succeeds Laurent Condomine, who will retire from the supervisory board after 11 years of leadership. Dr. Phillips will provide extensive guidance as the Company continues to advance its global development strategy with its planned second clinical registration pathway in head and neck cancer and its immunotherapy pathway as key focus areas.
“I am truly honored and excited by my appointment as chairman of the Nanobiotix supervisory board,” said Dr. Phillips. “I look forward to working with the board and the entire organization toward delivering the breakthrough promise of its potentially transformational technology. Overcoming cancer a
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board NANOBIOTIX (Euronext: NANO NASDAQ: NBTX the
Company ), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Gary Phillips, MD, has been appointed as the new chairman of the Company s supervisory board. Dr. Phillips succeeds Laurent Condomine, who will retire from the supervisory board after 11 years of leadership. Dr. Phillips will provide extensive guidance as the Company continues to advance its global development strategy with its planned second clinical registration pathway in head and neck cancer and its immunotherapy pathway as key focus areas.
Some cancers tied to sex are on the rise
HPV vaccine doesn’t offer blanket protection By CARLA K. JOHNSON, Associated Press
Published: May 25, 2021, 6:05am
Share: FILE - This undated image provided by Merck in October 2018 shows a vial and packaging for the Gardasil 9 vaccine. According to a study released on Wednesday, May 19, 2021, screening and the HPV vaccine have led to dramatic drops in cervical cancers over the last two decades in the U.S., but the gains are almost offset by a rise in other tumors caused by the virus. (Merck via AP)
Screening and the HPV vaccine have led to drops in cervical cancers over the last two decades in the U.S., a new study finds, but the gains are offset by a rise in other tumors caused by the virus.
Date Time
Share
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes.
Combination therapy of nivolumab and relatlimab before and after surgery is effective against melanoma (Abstract #9502)
In a Phase II study, MD Anderson researchers showed that a regimen of neoadjuvant and adjuvant treatment with checkpoint inhibitors nivolumab, a PD-1 inhibitor, and relatlimab, a LAG-3 inhibitor, was safe and effective in patients with resectable clinical stage III melanoma.
PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.